Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naïve patients with somatotroph adenomas

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 491-499

  Larkin, Sarah ^a   Reddy, Raghava ^b   Karavitaki, Niki ^b   Cudlip, Simon ^a   Wass, John ^b   Ansorge, Olaf ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; SOMATOSTATIN;

ACROMEGALY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INVASION; CLINICAL FEATURE; CODON; CONTROLLED STUDY; DENSELY SOMATOTROPH GRANULATED ADENOMA; ENDOCRINE FUNCTION TEST; FEMALE; GENE MUTATION; GENOTYPE; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OCTREOTIDE SUPPRESSION TEST; ONCOGENE; ONCOGENE GSP; PHENOTYPE; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPARSELY SOMATOTROPH GRANULATED ADENOMA; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; GRANULATION TISSUE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MIDDLE AGED; MUTATION; RECEPTORS, SOMATOTROPIN; RETROSPECTIVE STUDIES; SOMATOSTATIN; YOUNG ADULT;

EID: 84875156034     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0864     Document Type: Article

References (44)

1. Asa SL & Ezzat S. The pathogenesis of pituitary tumors. Annual Review of Pathology 2009 4 97-126. (doi:10.1146/annurev.pathol.4.110807.092259)
2. Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, Sakoguchi T, Sugiyama K, Kurisu K, Yasufuku-Takano J et al. Relationship between cytokeratin staining patterns and clinicopathological features in somatotropinomae. European Journal of Endocrinology 2010 163 531-539. (doi:10.1530/EJE-10-0586)
3. Fazekas I, Hegedus B, Bacsy E, Kerekes E, Slowik F, Balint K & Pasztor E. Characterization of human pituitary adenomas in cell cultures by light and electron microscopic morphology and immunolabeling. Folia Histochemica et Cytobiologica 2005 43 81-90.
4. Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurgical Focus 2010 29 E2. (doi:10.3171/2010.7.FOCUS10169)
5. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ & Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology 2007 156 203-216. (doi:10.1530/eje.1.02326)
6. Vallar L, Spada A & Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987 330 566-568. (doi:10.1038/330566a0)
7. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989 340 692-696. (doi:10.1038/340692a0)
8. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M & Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993 33 198-203. (doi:10.1227/00006123-199308000-00003)
9. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M & Faglia G. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. Journal of Clinical Endocrinology and Metabolism 1990 71 1421-1426. (doi:10.1210/jcem-71-6-1421)
10. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y & Choi Y. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. European Journal of Endocrinology 1996 134 720-726. (doi:10.1530/eje.0.1340720)
11. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J & Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical Endocrinology 2008 68 458-465. (doi:10.1111/j.1365-2265.2007. 03065.x)
12. Mendoza V, Sosa E, Espinosa-de-Los-Monteros AL, Salcedo M, Guinto G, Cheng S, Sandoval C & Mercado M. GSPa mutations in Mexican patients with acromegaly: potential impact on long term prognosis. Growth Hormone & IGF Research 2005 15 28-32. (doi:10.1016/j.ghir.2004.10.001)
13. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 6290-6295. (doi:10.1210/jc.2005-0998)
14. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG & Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 1995 133 686-690. (doi:10.1530/eje.0.1330686)
15. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ & Ezzat S. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Research 2007 67 7505-7511. (doi:10.1158/0008-5472.CAN-07-0219)
16. Fougner SL, Casar-Borota O, Heck A, Berg JP & Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clinical Endocrinology 2012 76 96-102. (doi:10.1111/j.1365-2265.2011.04163.x)
17. Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N & Budka H. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clinical Neuropathology 2001 20 163-171.
18. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M & Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 2008 19 82-91. (doi:10.1007/s12022-008-9029-z)
19. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J & Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. Journal of Clinical Endocrinology and Metabolism 2010 95 2334-2342. (doi:10.1210/jc.2009-2197)
20. ColaoA, Ferone D,Marzullo P & LombardiG. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
21. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K & DhilloWS. The effects of long-termgrowth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clinical Endocrinology 2011 75 220-225. (doi:10.1111/j.1365-2265.2011.04019.x)
22. Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008 159 89-95. (doi:10.1530/EJE-08-0267)
23. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE & Wass JA. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology 2005 62 282-288. (doi:10.1111/j.1365-2265.2004.02191.x)
24. Freda PU. Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018. (doi:10.1210/jc.87.7.3013)
25. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slowrelease octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563. (doi:10.1210/jc.2001-012012)
26. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME & Gagel RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995 80 2768-2775. (doi:10.1210/jc.80.9.2768)
27. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 295-303. (doi:10.1530/EJE-07-0562)
28. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocrine Pathology 2007 18 208-216. (doi:10.1007/s12022-007-9004-0)
29. Gilbert JA, Miell JP, Chambers SM, McGregor AM & Aylwin SJ. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clinical Endocrinology 2005 62 742-747. (doi:10.1111/j.1365-2265.2005.02278.x)
30. Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J & Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 2012 77 72-78. (doi:10.1111/j.1365- 2265.2011.04286.x)
31. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
32. Lundin P & Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528. (doi:10.1097/00004728-199207000-00004)
33. Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S & Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 1203-1210. (doi:10.1210/jc.2007-1986)
34. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism 2007 92 1592-1599. (doi:10.1210/jc.2006-2084)
35. Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T, Yamada S & Hirata Y. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocrine Journal 2011 59 221-228. (doi:10.1507/endocrj.EJ11-0177)
36. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR et al. Two G protein oncogenes in human endocrine tumors. Science 1990 249 655-659. (doi:10.1126/science.2116665)
37. Kola B, Korbonits M, Diaz-Cano S, Kaltsas G, Morris DG, Jordan S, Metherell L, Powell M, Czirjak S, Arnaldi G et al. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology 2003 59 328-338. (doi:10.1046/j.1365-2265.2003. 01851.x)
38. Billestrup N, Swanson LW & Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. PNAS 1986 83 6854-6857. (doi:10.1073/pnas.83.18.6854)
39. Ham J, Ivan M, Wynford-Thomas D & Scanlon MF. GH3 cells expressing constitutively active Gsa (Q227L) showenhanced hormone secretion and proliferation. Molecular and Cellular Endocrinology 1997 127 41-47. (doi:10.1016/S0303-7207(96)03987-1)
40. Lania A, Persani L, Ballare E, Mantovani S, Losa M & Spada A. Constitutively active Gsa is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1624-1628. (doi:10.1210/jc.83.5.1624)
41. Sano T, Rong QZ, Kagawa N & Yamada S. Down-regulation of E-cadherin and catenins in human pituitary growth hormoneproducing adenomas. Frontiers of Hormone Research 2004 32 127-132. (doi:10.1159/000079041)
42. Xu B, Sano T, Yoshimoto K & Yamada S. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocrine Pathology 2002 13 341-351. (doi:10.1385/EP:13:4:341)
43. Cavallaro U, Schaffhauser B & Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Letters 2002 176 123-128. (doi:10.1016/S0304-3835(01)00759-5)
44. Guarino M. Epithelial-mesenchymal transition and tumour invasion. International Journal of Biochemistry & Cell Biology 2007 39 2153-2160. (doi:10.1016/j.biocel.2007.07.011)